secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001213900-24-031371
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics receives FDA Orphan Drug Designation for tecarfarin in VAD patients
--------------------------------------------------------------------------------

- FDA granted ODD for tecarfarin to prevent thromboembolism/thrombosis in patients with LVADs, RVADs, biventricular assist devices, and total artificial hearts.
- ODD provides up to 7 years of U.S. market exclusivity after approval, tax credits for clinical research, and NDA user fee waiver.
- This is tecarfarin's second ODD; first was for prevention of systemic thromboembolism in ESKD/AFib patients.
- Warfarin achieves target anticoagulation only 56% of the time in VAD patients; DOACs like Eliquis are not indicated for VADs.
- Cadrenal CEO states company is dedicated to advancing tecarfarin through clinical development options as swiftly as possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024031371/0001213900-24-031371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390024031371/ea0203558-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-031371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer